Lung Cancer

Researchers conducting the VISTA-101 study will assess the safety and efficacy of KVA12123 alone and with Keytruda, in addition to determining the recommended dose of the therapy.

Treatment for patients with non-small cell lung cancer has evolved to include immunotherapy after surgery and chemotherapy.

Rybrevant outperformed other therapies for patients with exon 20 insertion-mutant, advanced non-small cell lung cancer in a clinical trial, highlighting the importance of personalized medicine.

Immunotherapy treatment with Opdivo before surgery improved recurrence-free survival and overall survival at five years in patients with non-small cell lung cancer.

The Food and Drug Administration will review Braftovi plus Mektovi for the treatment of patients with metastatic BRAF V600E-mutant non-small cell lung cancer.

Two-year follow-up data showed that Rybrevant was promising in a difficult-to-treat subtype of non-small cell lung cancer.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

From Robin Roberts providing an update on her partner, Amber Laign’s “rough year” with breast cancer, to Kathy Griffin’s suspected cause of lung cancer, here’s what’s happening in the oncology space this week.

Patients with resectable non-small cell lung cancer treated with Imfinzi plus chemo before surgery or as monotherapy after surgery demonstrated significant improvements to event-free survival compared with those treated with neoadjuvant chemotherapy and surgery, study results show.

Keytruda plus chemotherapy before surgery and as single agent after improved outcomes for patients with resectable non-small cell lung cancer.

Gefitinib plus chemotherapy could be considered a first-line treatment option for patients with EGFR-mutated NSCLC with brain metastases.

The first patient was enrolled in a three-drug clinical trial, which researchers hope will lend insight into immunotherapy resistance in lung cancer.

One of the trials investigating Keytruda has been discontinued because the drug did not significantly improve outcomes in patients with prostate cancer.

I’m in the race of cancer, hoping that a cure will pass the finish line before I do.

Chemotherapy affected my brain in ways that I was never told about.

Some patients with metastatic non-small cell lung cancer are not receiving effective therapies for their disease, the study authors suggested.

An expert discussed the recent approval of Keytruda for non-small cell lung cancer, and what patients with the disease need to know about the newly approved regimen.

Postmenopausal women cancer survivors, including lung, breast, colorectal and endometrial cancer, may have a greater physical function decline than is generally expected at their age, which may lead to lower quality of life after treatment.

Since 2015, the use of immunotherapies has increased for both young and older patients, but the survival benefit is more evident in younger patients, findings demonstrated.

A phase 3 trial will test datopotamab deruxtecan in combination with Keytruda with or without chemotherapy for certain patients with metastatic non-small cell lung cancer.

VIC-1911 will be studied alone or with Lumakras in patients with KRAS G12C-mutant non-small cell lung cancer.

The Food and Drug Administration approved Keytruda, an immunotherapy agent, for patients with stage 1B, 2 or 3A non-small cell lung cancer.

Researchers just launched a phase 2 trial evaluating iadademstat plus paclitaxel in patients with relapsed/refractory neuroendocrine cancer, including those with small cell lung cancer.

Patients with operable non-small cell lung cancer who were treated with an anti-PD-1 monoclonal antibody plus a doublet chemotherapy regiment did not experience cancer recurrence or new symptom onset during follow-up in a recent study.

The COVALENT-102 trial will investigate BMF-219 in patients with non-small cell lung cancer, colorectal and pancreatic cancers.

An expert explains what the FDA’s accelerated approval of Krazati means for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer and what he hopes will come next.

The indication for Pemfexy has been approved to include patients with metastatic, non-squamous, non-small cell lung cancer without EGFR or ALK genomic tumor mutations.

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

Krazati was granted an accelerated approval for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer, according to the Food and Drug Administration.

The recent FDA approval of Libtayo for advanced non-small cell lung cancer added yet another option for the treatment of patients with the disease.